Core Viewpoint - SciSparc Ltd. is expanding its joint venture MitoCareX Bio Ltd. to include research on pancreatic cancer following positive initial in-vitro results, indicating a significant growth in its therapeutic focus [1][2][3]. Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [6]. Research and Development - MitoCareX has achieved promising results in drug discovery for pancreatic cancer, utilizing a computationally advanced platform that screened millions of small molecules to identify potential anti-cancer treatments [2][3]. - The company is developing a predictive AI model to explore broader chemical spaces, aiming to discover novel anti-cancer compounds targeting the mitochondrial SLC25 protein family [4]. Market Context - Pancreatic cancer is noted as one of the most aggressive cancers, with a 5-year survival rate of only 12% as of 2023, highlighting a significant unmet medical need in this area [5].
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results